Modulating the innate immune response to influenza A virus: Potential therapeutic use of anti-inflammatory drugs

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Ramos, Irene ^a   Fernandez Sesma, Ana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory therapy; ARDS; Cytokines; Inflammation; Influenza virus; Innate immunity

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CHEMOKINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 BETA; PATTERN RECOGNITION RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RANTES; SIALIDASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR AGONIST; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE STORM; HUMAN; INFLAMMATION; INFLUENZA A; INNATE IMMUNITY; LUNG INJURY; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; REVIEW; TISSUE INJURY; VIRUS LOAD; VIRUS REPLICATION;

EID: 84938515799     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00361     Document Type: Review

References (246)

1. CDC. People at High Risk of Developing Flu-Related Complications (2015). Available from: http://www.cdc.gov/flu/about/disease/high_risk.htm
2. CDC. 2014-2015 Influenza season week 10 ending March 14, 2015. Fluview. Influenza Hospitalization Surveillance Network (FluSurv-NET) (2015). Available from: http://www.cdc.gov/flu/weekly/pdf/External_F1516.pdf
3. CDC. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep (2010) 59:1057-62.
4. Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 9:590-603. doi:10.1038/nrmicro2613
5. CDC. Interim Risk Assessment and Biosafety Level Recommendations for Working With Influenza A(H7N9) Viruses (2013). Available from: http://www.cdc.gov/flu/avianflu/h7n9/risk-assessment.htm
6. Van Kerkhove MD. Brief literature review for the WHO global influenza research agenda-highly pathogenic avian influenza H5N1 risk in humans. Influenza Other Respir Viruses (2013) 7(Suppl 2):26-33. doi:10.1111/irv.12077
7. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis (2005) 5:718-25. doi:10.1016/S1473-3099(05)70270-X
8. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine (2008) 26(Suppl 4):D59-66. doi:10.1016/j.vaccine.2008.07.025
9. Short KR, Kroeze EJ, Fouchier RA, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis (2014) 14:57-69. doi:10.1016/S1473-3099(13)70286-X
10. Bruder D, Srikiatkhachorn A, Enelow RI. Cellular immunity and lung injury in respiratory virus infection. Viral Immunol (2006) 19:147-55. doi:10.1089/vim.2006.19.147
11. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, Van Loo G, et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 133:235-49. doi:10.1016/j.cell.2008.02.043
12. Uiprasertkul M, Kitphati R, Puthavathana P, Kriwong R, Kongchanagul A, Ungchusak K, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis (2007) 13:708-12. doi:10.3201/eid1305.060572
13. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev (2006) 19:571-82. doi:10.1128/CMR.00058-05
14. Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, et al. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science (2013) 340:1230-4. doi:10.1126/science.1233632
15. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol (2014) 12:252-62. doi:10.1038/nrmicro3231
16. Goulding J, Godlee A, Vekaria S, Hilty M, Snelgrove R, Hussell T. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis (2011) 204:1086-94. doi:10.1093/infdis/jir467
17. Cohen M, Zhang XQ, Senaati HP, Chen HW, Varki NM, Schooley RT, et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J (2013) 10:321. doi:10.1186/1743-422X-10-321
18. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity (2013) 38:870-80. doi:10.1016/j.immuni.2013.05.004
19. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140:805-20. doi:10.1016/j.cell.2010.01.022
20. Lupfer C, Kanneganti TD. The expanding role of NLRs in antiviral immunity. Immunol Rev (2013) 255:13-24. doi:10.1111/imr.12089
21. Pothlichet J, Meunier I, Davis BK, Ting JP, Skamene E, Von Messling V, et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog (2013) 9:e1003256. doi:10.1371/journal.ppat.1003256
22. Allen IC, Scull MA, Moore CB, Holl EK, Mcelvania-Tekippe E, Taxman DJ, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity (2009) 30:556-65. doi:10.1016/j.immuni.2009.02.005
23. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol (2010) 11:404-10. doi:10.1038/ni.1861
24. Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton MT, et al. TLR2/MyD88/NF-kappaB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. PLoS One (2012) 7:e29695. doi:10.1371/journal.pone.0029695
25. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863
26. Kulkarni R, Behboudi S, Sharif S. Insights into the role of toll-like receptors in modulation of T cell responses. Cell Tissue Res (2011) 343:141-52. doi:10.1007/s00441-010-1017-1
27. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity (2010) 32:305-15. doi:10.1016/j.immuni.2010.03.012
28. Kingeter LM, Lin X. C-type lectin receptor-induced NF-kappaB activation in innate immune and inflammatory responses. Cell Mol Immunol (2012) 9:105-12. doi:10.1038/cmi.2011.58
29. Wang SF, Huang JC, Lee YM, Liu SJ, Chan YJ, Chau YP, et al. DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. Biochem Biophys Res Commun (2008) 373:561-6. doi:10.1016/j.bbrc.2008.06.078
30. Londrigan SL, Turville SG, Tate MD, Deng YM, Brooks AG, Reading PC. N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN. J Virol (2011) 85:2990-3000. doi:10.1128/JVI.01705-10
31. Ramos I, Fernandez-Sesma A. Cell receptors for influenza a viruses and the innate immune response. Front Microbiol (2012) 3:117. doi:10.3389/fmicb.2012.00117
32. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol (2014) 14:315-28. doi:10.1038/nri3665
33. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol (2012) 12:295-305. doi:10.1038/nri3166
34. Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, Pitcher LA, Degn SE, Turley SJ, et al. Complement-dependent transport of antigen into B cell follicles. J Immunol (2010) 185:2659-64. doi:10.4049/jimmunol.1000522
35. Chiu C, Openshaw PJ. Antiviral B cell and T cell immunity in the lungs. Nat Immunol (2015) 16:18-26. doi:10.1038/ni.3056
36. Piwpankaew Y, Monteerarat Y, Suptawiwat O, Puthavathana P, Uipresertkul M, Auewarakul P. Distribution of viral RNA, sialic acid receptor, and pathology in H5N1 avian influenza patients. APMIS (2010) 118:895-902. doi:10.1111/j.1600-0463.2010.02676.x
37. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol (2010) 177:166-75. doi:10.2353/ajpath.2010.100115
38. Weinheimer VK, Becher A, Tonnies M, Holland G, Knepper J, Bauer TT, et al. Influenza A viruses target type II pneumocytes in the human lung. J Infect Dis (2012) 206:1685-94. doi:10.1093/infdis/jis455
39. Ramos I, Fernandez-Sesma A. Innate immunity to H5N1 influenza viruses in humans. Viruses (2012) 4:3363-88. doi:10.3390/v4123363
40. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol (2014) 5:352. doi:10.3389/fphys.2014.00352
41. Ye S, Lowther S, Stambas J. Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3. J Virol (2015) 89:2672-83. doi:10.1128/JVI.03529-14
42. Shen HM, Pervaiz S. TNF receptor superfamily-induced cell death: redox-dependent execution. FASEB J (2006) 20:1589-98. doi:10.1096/fj.05-5603rev
43. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity (1996) 4:387-96. doi:10.1016/S1074-7613(00)80252-6
44. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ (2012) 19:75-86. doi:10.1038/cdd.2011.164
45. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe?. Trends Immunol (2009) 30:574-84. doi:10.1016/j.it.2009.09.004
46. Shen Y, Lu H, Qi T, Gu Y, Xiang M, Lu S, et al. Fatal cases of human infection with avian influenza A (H7N9) virus in Shanghai, China in 2013. Biosci Trends (2015) 9:73-8. doi:10.5582/bst.2014.01113
47. Mauad T, Hajjar LA, Callegari GD, Da Silva LF, Schout D, Galas FR, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med (2010) 181:72-9. doi:10.1164/rccm.200909-1420OC
48. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis (2010) 50:850-9. doi:10.1086/650581
49. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol (2008) 3:499-522. doi:10.1146/annurev.pathmechdis.3.121806.154316
50. Guarner J, Falcon-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res (2009) 40:655-61. doi:10.1016/j.arcmed.2009.10.001
51. Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JF, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis (2013) 57:1449-57. doi:10.1093/cid/cit541
52. Gao R, Bhatnagar J, Blau DM, Greer P, Rollin DC, Denison AM, et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis. Am J Pathol (2013) 183:1258-68. doi:10.1016/j.ajpath.2013.06.023
53. Bermejo-Martin JF, Ortiz De Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care (2009) 13:R201. doi:10.1186/cc8208
54. Tiwari N, Kapoor P, Dhole TN. Antibody and inflammatory response-mediated severity of pandemic 2009 (pH1N1) influenza virus. J Med Virol (2014) 86:1034-40. doi:10.1002/jmv.23877
55. Chiaretti A, Pulitano S, Barone G, Ferrara P, Romano V, Capozzi D, et al. IL-1 beta and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators Inflamm (2013) 2013:495848. doi:10.1155/2013/495848
56. Yu X, Zhang X, Zhao B, Wang J, Zhu Z, Teng Z, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS One (2011) 6:e28680. doi:10.1371/journal.pone.0028680
57. Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, Brezoszki ES, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care (2010) 14:R203. doi:10.1186/cc9324
58. Bian JR, Nie W, Zang YS, Fang Z, Xiu QY, Xu XX. Clinical aspects and cytokine response in adults with seasonal influenza infection. Int J Clin Exp Med (2014) 7:5593-602.
59. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet (2004) 363:617-9. doi:10.1016/S0140-6736(04)15595-5
60. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med (2006) 12:1203-7. doi:10.1038/nm1477
61. Deng R, Lu M, Korteweg C, Gao Z, Mcnutt MA, Ye J, et al. Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patients. J Pathol (2008) 216:328-36. doi:10.1002/path.2417
62. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A (2014) 111:769-74. doi:10.1073/pnas.1321748111
63. Shen Z, Chen Z, Li X, Xu L, Guan W, Cao Y, et al. Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection. Clin Microbiol Infect (2014) 20:O493-500. doi:10.1111/1469-0691.12505
64. Ramos I, Bernal-Rubio D, Durham N, Belicha-Villanueva A, Lowen AC, Steel J, et al. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. J Virol (2011) 85:4421-31. doi:10.1128/JVI.02356-10
65. Kim KS, Jung H, Shin IK, Choi BR, Kim DH. Induction of interleukin-1 beta (IL-1beta) is a critical component of lung inflammation during influenza A (H1N1) virus infection. J Med Virol (2015) 87(7):1104-12. doi:10.1002/jmv.24138
66. Venkatesha SH, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci (2015) 16:887-906. doi:10.3390/ijms16010887
67. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ (2003) 10:45-65. doi:10.1038/sj.cdd.4401189
68. Sethu S, Melendez AJ. New developments on the TNFalpha-mediated signalling pathways. Biosci Rep (2011) 31:63-76. doi:10.1042/BSR20100040
69. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science (2002) 296:1634-5. doi:10.1126/science.1071924
70. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell (2002) 109(Suppl):S81-96. doi:10.1016/S0092-8674(02)00703-1
71. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 124:823-35. doi:10.1016/j.cell.2006.02.016
72. Thorburn A. Death receptor-induced cell killing. Cell Signal (2004) 16:139-44. doi:10.1016/j.cellsig.2003.08.007
73. Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem (2004) 279:10822-8. doi:10.1074/jbc.M313141200
74. Morgan MJ, Kim YS, Liu ZG. TNFalpha and reactive oxygen species in necrotic cell death. Cell Res (2008) 18:343-9. doi:10.1038/cr.2008.31
75. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature (2015) 517:311-20. doi:10.1038/nature14191
76. Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells (2010) 30:1-12. doi:10.1007/s10059-010-0105-0
77. Newburger PE, Dai Q, Whitney C. In vitro regulation of human phagocyte cytochrome b heavy and light chain gene expression by bacterial lipopolysaccharide and recombinant human cytokines. J Biol Chem (1991) 266:16171-7.
78. Moe KT, Aulia S, Jiang F, Chua YL, Koh TH, Wong MC, et al. Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med (2006) 10:231-9. doi:10.1111/j.1582-4934.2006.tb00304.x
79. Muller M, Althaus R, Frohlich D, Frei K, Eugster HP. Reduced antilisterial activity of TNF-deficient bone marrow-derived macrophages is due to impaired superoxide production. Eur J Immunol (1999) 29:3089-97. doi:10.1002/(SICI)1521-4141(199910)29:10<3089::AID-IMMU3089>3.0.CO;2-D
80. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. QJM (2010) 103:917-28. doi:10.1093/qjmed/hcq152
81. Shi X, Zhou W, Huang H, Zhu H, Zhou P, Zhu H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care (2013) 17:R301. doi:10.1186/cc13171
82. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest (1998) 101:311-20. doi:10.1172/JCI1368
83. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 1813:878-88. doi:10.1016/j.bbamcr.2011.01.034
84. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res (2014) 2:288-94. doi:10.1158/2326-6066.CIR-14-0022
85. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol (2014) 26:2-12. doi:10.1016/j.smim.2013.11.002
86. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 374:1-20. doi:10.1042/BJ20030407
87. Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, et al. Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene (2004) 23:3368-75. doi:10.1038/sj.onc.1207459
88. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 78:1349-54. doi:10.1172/JCI112721
89. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A (1987) 84:7251-5. doi:10.1073/pnas.84.20.7251
90. Jain S, Gautam V, Naseem S. Acute-phase proteins: as diagnostic tool. J Pharm Bioallied Sci (2011) 3:118-27. doi:10.4103/0975-7406.76489
91. Agassandian M, Shurin GV, Ma Y, Shurin MR. C-reactive protein and lung diseases. Int J Biochem Cell Biol (2014) 53:77-88. doi:10.1016/j.biocel.2014.05.016
92. Zimmerman O, Rogowski O, Aviram G, Mizrahi M, Zeltser D, Justo D, et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection. BMC Infect Dis (2010) 10:288. doi:10.1186/1471-2334-10-288
93. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest (2009) 136:471-80. doi:10.1378/chest.08-2413
94. Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol (2015) 27:21-9. doi:10.1093/intimm/dxu081
95. Lauder SN, Jones E, Smart K, Bloom A, Williams AS, Hindley JP, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol (2013) 43:2613-25. doi:10.1002/eji.201243018
96. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 117:3720-32. doi:10.1182/blood-2010-07-273417
97. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol (2010) 80:1981-91. doi:10.1016/j.bcp.2010.06.020
98. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal (2010) 3:cm1. doi:10.1126/scisignal.3105cm1
99. Wang X, Feuerstein GZ, Gu JL, Lysko PG, Yue TL. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis (1995) 115:89-98. doi:10.1016/0021-9150(94)05503-B
100. Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 11:633-52. doi:10.1038/nrd3800
101. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol (2002) 20:S1-13.
102. McAuley JL, Tate MD, Mackenzie-Kludas CJ, Pinar A, Zeng W, Stutz A, et al. Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS Pathog (2013) 9:e1003392. doi:10.1371/journal.ppat.1003392
103. Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Brain Res (1997) 776:96-104. doi:10.1016/S0006-8993(97)01009-3
104. Kozak W, Zheng H, Conn CA, Soszynski D, Van Der Ploeg LH, Kluger MJ. Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1 beta-deficient mice. Am J Physiol (1995) 269:R969-77.
105. Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity (2009) 30:566-75. doi:10.1016/j.immuni.2009.02.006
106. Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir Crit Care Med (2001) 163:1384-8. doi:10.1164/ajrccm.163.6.2006131
107. Geiser T. Mechanisms of alveolar epithelial repair in acute lung injury-a translational approach. Swiss Med Wkly (2003) 133:586-90.
108. Thickett DR, Perkins GD. IL1 may be elevated but is it all bad in ARDS?. Thorax (2008) 63:750-1.
109. Geiser T, Jarreau PH, Atabai K, Matthay MA. Interleukin-1beta augments in vitro alveolar epithelial repair. Am J Physiol Lung Cell Mol Physiol (2000) 279:L1184-90.
110. Sanchez-Guerrero E, Chen E, Kockx M, An SW, Chong BH, Khachigian LM. IL-1beta signals through the EGF receptor and activates Egr-1 through MMP-ADAM. PLoS One (2012) 7:e39811. doi:10.1371/journal.pone.0039811
111. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol (2011) 1:476-86. doi:10.1016/j.coviro.2011.11.001
112. Schreiber G, Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol (2015) 36:139-49. doi:10.1016/j.it.2015.01.002
113. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 3:651-62. doi:10.1038/nrm909
114. Knight E Jr, Korant BD. Fibroblast interferon induces synthesis of four proteins in human fibroblast cells. Proc Natl Acad Sci U S A (1979) 76:1824-7. doi:10.1073/pnas.76.4.1824
115. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14:36-49. doi:10.1038/nri3581
116. Wesoly J, Szweykowska-Kulinska Z, Bluyssen HA. STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol (2007) 54:27-38.
117. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem (2006) 281:14111-8. doi:10.1074/jbc.M511797200
118. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2003) 4:69-77. doi:10.1038/ni875
119. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2003) 4:63-8. doi:10.1038/ni873
120. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. J Interferon Cytokine Res (2010) 30:573-8. doi:10.1089/jir.2010.0063
121. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science (1994) 264:1918-21. doi:10.1126/science.8009221
122. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol (2005) 5:675-87. doi:10.1038/nri1684
123. Davidson S, Crotta S, Mccabe TM, Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun (2014) 5:3864. doi:10.1038/ncomms4864
124. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol (2014) 192:5459-68. doi:10.4049/jimmunol.1002795
125. Rodriguez-Carrio J, Lopez P, Suarez A. Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. Clin Sci (Lond) (2015) 128:449-64. doi:10.1042/CS20140554
126. Rice GI, Forte GM, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 12:1159-69. doi:10.1016/S1474-4422(13)70258-8
127. Stockinger S, Materna T, Stoiber D, Bayr L, Steinborn R, Kolbe T, et al. Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenes. J Immunol (2002) 169:6522-9. doi:10.4049/jimmunol.169.11.6522
128. Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am J Med Sci (2014) 348:168-75. doi:10.1097/MAJ.0000000000000284
129. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 4:e1000151. doi:10.1371/journal.ppat.1000151
130. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75:163-89. doi:10.1189/jlb.0603252
131. Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G. The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev (1997) 8:189-206. doi:10.1016/S1359-6101(97)00009-9
132. Fujimaki H, Hikawa N, Nagoya M, Nagata T, Minami M. IFN-gamma induces expression of MHC class I molecules in adult mouse dorsal root ganglion neurones. Neuroreport (1996) 7:2951-5. doi:10.1097/00001756-199611250-00030
133. Rosa FM, Fellous M. Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control. J Immunol (1988) 140:1660-4.
134. Aki M, Shimbara N, Takashina M, Akiyama K, Kagawa S, Tamura T, et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (1994) 115:257-69.
135. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol (1999) 11:76-81. doi:10.1016/S0952-7915(99)80014-4
136. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 16:76-81. doi:10.1016/j.coi.2003.11.004
137. Kowanko IC, Ferrante A. Stimulation of neutrophil respiratory burst and lysosomal enzyme release by human interferon-gamma. Immunology (1987) 62:149-51.
138. Ellis TN, Beaman BL. Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology (2004) 112:2-12. doi:10.1111/j.1365-2567.2004.01849.x
139. Reshi ML, Su YC, Hong JR. RNA viruses: ROS-mediated cell death. Int J Cell Biol (2014) 2014:467452. doi:10.1155/2014/467452
140. Lee JY, Goldman D, Piliero LM, Petri M, Sullivan KE. Interferon-gamma polymorphisms in systemic lupus erythematosus. Genes Immun (2001) 2:254-7. doi:10.1038/sj.gene.6363775
141. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 1:893-5. doi:10.1016/S0140-6736(87)92863-7
142. Bruserud O, Kittang AO. The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol (2010) 341:3-12. doi:10.1007/82_2010_18
143. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol (1988) 141:1018-25.
144. Maghazachi AA, Al-Aoukaty A, Schall TJ. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol (1994) 153:4969-77.
145. Keophiphath M, Rouault C, Divoux A, Clement K, Lacasa D. CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler Thromb Vasc Biol (2010) 30:39-45. doi:10.1161/ATVBAHA.109.197442
146. Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets (2013) 17:1439-60. doi:10.1517/14728222.2013.837886
147. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272:1955-8. doi:10.1126/science.272.5270.1955
148. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 11:1170-2. doi:10.1038/nm1319
149. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol (2011) 162:1453-69. doi:10.1111/j.1476-5381.2010.01147.x
150. Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol (2008) 172:1155-70. doi:10.2353/ajpath.2008.070791
151. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol (2000) 156:1951-9. doi:10.1016/S0002-9440(10)65068-7
152. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. J Neurosci Res (1998) 54:169-80. doi:10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C
153. Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale M Jr, et al. Direct, interferon-independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection. J Virol (2014) 88:1582-90. doi:10.1128/JVI.02007-13
154. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev (2011) 22:121-30. doi:10.1016/j.cytogfr.2011.06.001
155. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev (2014) 13:272-80. doi:10.1016/j.autrev.2013.10.010
156. Ichikawa A, Kuba K, Morita M, Chida S, Tezuka H, Hara H, et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med (2013) 187:65-77. doi:10.1164/rccm.201203-0508OC
157. Gales D, Clark C, Manne U, Samuel T. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol (2013) 2013:859154. doi:10.1155/2013/859154
158. Julkunen I, Melen K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine (2000) 19(Suppl 1):S32-7. doi:10.1016/S0264-410X(00)00275-9
159. Matsukura S, Kokubu F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy Clin Immunol (1996) 98:1080-7. doi:10.1016/S0091-6749(96)80195-3
160. Casola A, Garofalo RP, Jamaluddin M, Vlahopoulos S, Brasier AR. Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression. J Immunol (2000) 164:5944-51. doi:10.4049/jimmunol.164.11.5944
161. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, Brasier A, et al. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol (2007) 81:309-18. doi:10.1128/JVI.01411-06
162. Vogel AJ, Harris S, Marsteller N, Condon SA, Brown DM. Early cytokine dysregulation and viral replication are associated with mortality during lethal influenza infection. Viral Immunol (2014) 27:214-24. doi:10.1089/vim.2013.0095
163. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS?. Am J Physiol Lung Cell Mol Physiol (2014) 306:L217-30. doi:10.1152/ajplung.00311.2013
164. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med (2001) 163:463-8. doi:10.1164/ajrccm.163.2.2005109
165. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 404:407-11. doi:10.1038/35006097
166. Panganiban RP, Vonakis BM, Ishmael FT, Stellato C. Coordinated post-transcriptional regulation of the chemokine system: messages from CCL2. J Interferon Cytokine Res (2014) 34:255-66. doi:10.1089/jir.2013.0149
167. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res (2009) 29:313-26. doi:10.1089/jir.2008.0027
168. Rose CE Jr, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation (2003) 10:273-88. doi:10.1038/sj.mn.7800193
169. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation (2003) 10:247-57. doi:10.1080/713773639
170. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab (2010) 30:459-73. doi:10.1038/jcbfm.2009.240
171. Wain JH, Kirby JA, Ali S. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1,-2,-3 and-4. Clin Exp Immunol (2002) 127:436-44. doi:10.1046/j.1365-2249.2002.01764.x
172. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab (2005) 25:593-606. doi:10.1038/sj.jcbfm.9600055
173. Damjanovic D, Divangahi M, Kugathasan K, Small CL, Zganiacz A, Brown EG, et al. Negative regulation of lung inflammation and immunopathology by TNF-alpha during acute influenza infection. Am J Pathol (2011) 179:2963-76. doi:10.1016/j.ajpath.2011.09.003
174. Narasaraju T, Ng HH, Phoon MC, Chow VT. MCP-1 antibody treatment enhances damage and impedes repair of the alveolar epithelium in influenza pneumonitis. Am J Respir Cell Mol Biol (2010) 42:732-43. doi:10.1165/rcmb.2008-0423OC
175. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev (2002) 13:455-81. doi:10.1016/S1359-6101(02)00045-X
176. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature (1993) 361:79-82. doi:10.1038/361079a0
177. Guan E, Wang J, Roderiquez G, Norcross MA. Natural truncation of the chemokine MIP-1 beta/CCL4 affects receptor specificity but not anti-HIV-1 activity. J Biol Chem (2002) 277:32348-52. doi:10.1074/jbc.M203077200
178. Vila LM, Molina MJ, Mayor AM, Cruz JJ, Rios-Olivares E, Rios Z. Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol (2007) 26:718-22. doi:10.1007/s10067-006-0387-y
179. Tang BM, Craig JC, Eslick GD, Seppelt I, Mclean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med (2009) 37:1594-603. doi:10.1097/CCM.0b013e31819fb507
180. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 353:1374-85. doi:10.1056/NEJMra052211
181. Quispe-Laime AM, Bracco JD, Barberio PA, Campagne CG, Rolfo VE, Umberger R, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med (2010) 36:33-41. doi:10.1007/s00134-009-1727-6
182. Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses (2013) 7(Suppl 3):52-9. doi:10.1111/irv.12171
183. Kudo K, Takasaki J, Manabe T, Uryu H, Yamada R, Kuroda E, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One (2012) 7:e32280. doi:10.1371/journal.pone.0032280
184. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis (2009) 200:492-500. doi:10.1086/600383
185. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med (2011) 183:1207-14. doi:10.1164/rccm.201101-0110OC
186. Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep (2014) 4:7176. doi:10.1038/srep07176
187. Zhang Y, Sun W, Svendsen ER, Tang S, Macintyre RC, Yang P, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection?. A meta-analysis. Crit Care (2015) 19:46. doi:10.1186/s13054-015-0764-5
188. Shodell M, Siegal FP. Corticosteroids depress IFN-alpha-producing plasmacytoid dendritic cells in human blood. J Allergy Clin Immunol (2001) 108:446-8. doi:10.1067/mai.2001.117928
189. WHO. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009: Influenza and Other Influenza Viruses. Geneva: World Health Organization (2009).
190. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 106:2104-10. doi:10.1161/01.CIR.0000034048.38910.91
191. Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int (2014) 2014:872370. doi:10.1155/2014/872370
192. Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol (2014) 63:2491-502. doi:10.1016/j.jacc.2014.01.054
193. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis (2012) 205:13-9. doi:10.1093/infdis/jir695
194. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 131:1006-12. doi:10.1378/chest.06-1997
195. Carrillo-Esper R, Sosa-Garcia JO, Arch-Tirado E. [Experience in the management of the severe form of human influenza A H1N1 pneumonia in an intensive care unit]. Cir Cir (2011) 79:409-16.
196. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, Jehring D, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect (2010) 138:1281-8. doi:10.1017/S0950268810000105
197. Viasus D, Pano-Pardo JR, Cordero E, Campins A, Lopez-Medrano F, Villoslada A, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect (2011) 62:193-9. doi:10.1016/j.jinf.2011.01.014
198. Mehrbod P, Hair-Bejo M, Tengku Ibrahim TA, Omar AR, El Zowalaty M, Ajdari Z, et al. Simvastatin modulates cellular components in influenza A virus-infected cells. Int J Mol Med (2014) 34:61-73. doi:10.3892/ijmm.2014.1761
199. Liu Z, Guo Z, Wang G, Zhang D, He H, Li G, et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci (2009) 38:215-23. doi:10.1016/j.ejps.2009.07.004
200. Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J. Protective effect of fluvastatin on influenza virus infection. Mol Med Rep (2014) 9:2221-6. doi:10.3892/mmr.2014.2076
201. Hsu BG, Yang FL, Lee RP, Peng TC, Harn HJ, Chen HI. N-acetylcysteine ameliorates lipopolysaccharide-induced organ damage in conscious rats. J Biomed Sci (2004) 11:152-62. doi:10.1007/BF02256558
202. Hsu BG, Lee RP, Yang FL, Harn HJ, Chen HI. Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci (2006) 79:2010-6. doi:10.1016/j.lfs.2006.06.040
203. Kao SJ, Wang D, Lin HI, Chen HI. N-acetylcysteine abrogates acute lung injury induced by endotoxin. Clin Exp Pharmacol Physiol (2006) 33:33-40. doi:10.1111/j.1440-1681.2006.04320.x
204. Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol (2010) 79:413-20. doi:10.1016/j.bcp.2009.08.025
205. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol (2011) 82:548-55. doi:10.1016/j.bcp.2011.05.014
206. Ghezzi P, Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol (2004) 17:99-102.
207. Garigliany MM, Desmecht DJ. N-acetylcysteine lacks universal inhibitory activity against influenza A viruses. J Negat Results Biomed (2011) 10:5. doi:10.1186/1477-5751-10-5
208. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J (1997) 10:1535-41. doi:10.1183/09031936.97.10071535
209. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun (2000) 267:124-8. doi:10.1006/bbrc.1999.1917
210. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother (2002) 49:745-55. doi:10.1093/jac/dkf008
211. Zhao DM, Xue HH, Chida K, Suda T, Oki Y, Kanai M, et al. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol (2000) 278:L726-36.
212. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev (2010) 23:590-615. doi:10.1128/CMR.00078-09
213. Miyamoto D, Hasegawa S, Sriwilaijaroen N, Yingsakmongkon S, Hiramatsu H, Takahashi T, et al. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull (2008) 31:217-22. doi:10.1248/bpb.31.217
214. Sugamata R, Sugawara A, Nagao T, Suzuki K, Hirose T, Yamamoto K, et al. Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression. J Antibiot (Tokyo) (2014) 67:213-22. doi:10.1038/ja.2013.132
215. Azuma A, Yamaya M, Kadota J, Mikasa K, Kudoh S; Influenza Practical Treatment Workshop on New Targets of Macrolides. Use of macrolides in the 2009 H1N1 virus infection outbreak: a survey of general practices in Japan. Respir Investig (2013) 51:257-9. doi:10.1016/j.resinv.2013.04.002
216. Higashi F, Kubo H, Yasuda H, Nukiwa T, Yamaya M. Additional treatment with clarithromycin reduces fever duration in patients with influenza. Respir Investig (2014) 52:302-9. doi:10.1016/j.resinv.2014.05.001
217. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A (2011) 108:5354-9. doi:10.1073/pnas.1019378108
218. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity (2012) 37:158-70. doi:10.1016/j.immuni.2012.04.011
219. Perez-Sala D, Lamas S. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid Redox Signal (2001) 3:231-48. doi:10.1089/152308601300185197
220. Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol (2005) 175:6878-84. doi:10.4049/jimmunol.175.10.6878
221. Lee SM, Cheung CY, Nicholls JM, Hui KP, Leung CY, Uiprasertkul M, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis (2008) 198:525-35. doi:10.1086/590499
222. Lee MY, Cheung CY, Peiris JS. Role of cyclooxygenase-2 in H5N1 viral pathogenesis and the potential use of its inhibitors. Hong Kong Med J (2013) 19(Suppl 4):29-35.
223. Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res (2011) 91:330-4. doi:10.1016/j.antiviral.2011.07.011
224. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A (2008) 105:8091-6. doi:10.1073/pnas.0711942105
225. Eyers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J R Soc Med (2010) 103:403-11. doi:10.1258/jrsm.2010.090441
226. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit?. Biology, clinical experience, and future prospects. Am Heart J (2012) 164:672-80. doi:10.1016/j.ahj.2012.06.023
227. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses (2010) 4:307-11. doi:10.1111/j.1750-2659.2010.00155.x
228. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mullbacher A, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother (2007) 51:2965-8. doi:10.1128/AAC.00219-07
229. Aldridge JR Jr, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 106:5306-11. doi:10.1073/pnas.0900655106
230. Cloutier A, Marois I, Cloutier D, Verreault C, Cantin AM, Richter MV. The prostanoid 15-deoxy-Delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J Infect Dis (2012) 205:621-30. doi:10.1093/infdis/jir804
231. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res (2013) 99:417-35. doi:10.1016/j.antiviral.2013.06.018
232. Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, Hatta Y, et al. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol (2008) 74:896-903. doi:10.1124/mol.108.048769
233. Marsolais D, Hahm B, Walsh KB, Edelmann KH, Mcgavern D, Hatta Y, et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A (2009) 106:1560-5. doi:10.1073/pnas.0812689106
234. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A (2011) 108:12018-23. doi:10.1073/pnas.1107024108
235. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res (2011) 51:15-25. doi:10.1007/s12026-011-8240-z
236. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell (2011) 146:980-91. doi:10.1016/j.cell.2011.08.015
237. Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A (2014) 111:3799-804. doi:10.1073/pnas.1400593111
238. Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, et al. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology (2014) 45(2-453):152-7. doi:10.1016/j.virol.2014.01.003
239. Roberts E, Guerrero M, Urbano M, Rosen H. Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012). Expert Opin Ther Pat (2013) 23:817-41. doi:10.1517/13543776.2013.783022
240. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem (2002) 131:773-9. doi:10.1093/oxfordjournals.jbchem.a003164
241. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis (2002) 186:341-50. doi:10.1086/341462
242. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov (2008) 2:72-6. doi:10.2174/187221308783399306
243. Garcia CC, Russo RC, Guabiraba R, Fagundes CT, Polidoro RB, Tavares LP, et al. Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice. PLoS Pathog (2010) 6:e1001171. doi:10.1371/journal.ppat.1001171
244. Vlahos R, Selemidis S. NADPH oxidases as novel pharmacologic targets against influenza A virus infection. Mol Pharmacol (2014) 86:747-59. doi:10.1124/mol.114.095216
245. Sharma G, Sharma DC, Fen LH, Pathak M, Bethur N, Pendharkar V, et al. Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor. Emerg Microbes Infect (2013) 2:e54. doi:10.1038/emi.2013.52
246. Liu KC, Fang JM, Jan JT, Cheng TJ, Wang SY, Yang ST, et al. Enhanced anti-influenza agents conjugated with anti-inflammatory activity. J Med Chem (2012) 55:8493-501. doi:10.1021/jm3009844